ID   SK-N-MC-IXC
AC   CVCL_1398
SY   MC-IXC; MCIXC
DR   BTO; BTO:0005372
DR   CLO; CLO_0007615
DR   EFO; EFO_0002230
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ATCC; CRL-2270
DR   BioGRID_ORCS_Cell_line; 939
DR   BioSample; SAMN03472918
DR   cancercelllines; CVCL_1398
DR   Cell_Model_Passport; SIDM01246
DR   ChEMBL-Cells; CHEMBL3308758
DR   ChEMBL-Targets; CHEMBL1075495
DR   Cosmic; 688068
DR   Cosmic; 908118
DR   Cosmic-CLP; 908118
DR   DepMap; ACH-002160
DR   GDSC; 908118
DR   GEO; GSM1670077
DR   IGRhCellID; MCIXC
DR   LINCS_LDP; LCL-1967
DR   PharmacoDB; MCIXC_886_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1398
DR   PubChem_Cell_line; CVCL_1398
DR   TOKU-E; 4055
DR   Wikidata; Q54954480
RX   PubMed=4748425;
RX   PubMed=15892104;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=25877200;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=35839778;
WW   https://www.mskcc.org/research-advantage/support/technology/tangible-material/sk-n-mc-ixc-human-neuroblastoma-cell-line
CC   Problematic cell line: Misclassified. Parent cell line (SK-N-MC) was originally thought to be a neuroblastoma cell line but shown to be from an Askin tumor.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK2010-067.
CC   Population: Caucasian.
CC   Microsatellite instability: Instable (MSI-low) (Sanger).
CC   Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.170_572del; Zygosity=Unspecified (from parent cell line).
CC   Omics: Array-based CGH.
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=0%; East Asian, South=0%; South Asian=0%; European, North=74.37%; European, South=25.63% (PubMed=30894373).
CC   Derived from site: Metastatic; Orbital region; UBERON=UBERON_0004088.
ST   Source(s): ATCC; Cosmic-CLP; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 11
ST   D16S539: 12
ST   D18S51: 13,14,15
ST   D19S433: 13,15.2
ST   D21S11: 30,31.2
ST   D2S1338: 17,21
ST   D3S1358: 15
ST   D5S818: 11
ST   D7S820: 8
ST   D8S1179: 10
ST   FGA: 21,25
ST   Penta D: 9,13
ST   Penta E: 16,18
ST   TH01: 9.3
ST   TPOX: 9,11
ST   vWA: 17,18
DI   NCIt; C7542; Askin tumor
DI   ORDO; Orphanet_370348; Peripheral primitive neuroectodermal tumor
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0530 ! SK-N-MC
SX   Female
AG   12Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 38
//
RX   PubMed=4748425;
RA   Biedler J.L., Helson L., Spengler B.A.;
RT   "Morphology and growth, tumorigenicity, and cytogenetics of human
RT   neuroblastoma cells in continuous culture.";
RL   Cancer Res. 33:2643-2652(1973).
//
RX   PubMed=15892104; DOI=10.1002/gcc.20198;
RA   Mosse Y.P., Greshock J., Margolin A.A., Naylor T., Cole K., Khazi D.,
RA   Hii G., Winter C., Shahzad S., Asziz M.U., Biegel J.A., Weber B.L.,
RA   Maris J.M.;
RT   "High-resolution detection and mapping of genomic DNA alterations in
RT   neuroblastoma.";
RL   Genes Chromosomes Cancer 43:390-403(2005).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//